Article thumbnail

Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study

By Elizabeth C Russell, Salome Charalambous, Lindiwe Pemba, Gavin J Churchyard, Alison D Grant and Katherine Fielding
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). Anglaret X: Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS
  2. (2008). Anglaret X: Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d’Ivoire: 2-year outcomes and determinants. AIDS
  3. (2006). C: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet
  4. (2007). Churchyard GJ: Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care
  5. (2007). CJ: Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med
  6. (2001). Deficiency Anaemia. Assessment, Prevention and Control: A Guide for programme managers WHO
  7. (2006). E: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS
  8. (2005). Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS
  9. (2008). Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.
  10. (2008). Fact Sheets on HIV and AIDS,
  11. Freedberg KA: Predictors of mortality in patients initiating antiretroviral therapy
  12. (2004). Goemaere E: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS
  13. (2005). Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr
  14. (2008). Kimaiyo S: Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One
  15. (2002). Lackritz E: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. Lancet
  16. (2009). Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg
  17. (2006). Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and highincome countries. Lancet
  18. (1987). Multiple Imputation for nonresponse in surveys
  19. (2004). Multiple Imputation of missing values.
  20. (2008). Ndwapi N: Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One
  21. (2008). Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis
  22. (2008). Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther
  23. (2006). Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA
  24. (2008). Report in the global AIDS epidemic UNAIDS
  25. (2007). Report on Declaration of Commitment on HIV and AIDS - South Africa.
  26. (2009). Short-term and longterm risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.
  27. (2008). WD: Characteristics and outcomes of adult patients lost to followup at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr
  28. (2006). WM: Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS